Trial
NCT02956486
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Eisai Co., Ltd.
Collaborators
Biogen
Condition
Alzheimer's Disease
Intervention
Elenbecestat
Why stopped
Due to an unfavorable risk-benefit ratio including no evidence of potential efficacy, and the adverse event profile of E2609 being worse than placebo.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-02-03